These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 26705445)

  • 21. Triple Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% for Acne: Efficacy and Safety from a Pooled Phase 3 Analysis.
    Kircik LH; Stein Gold L; Gold M; Weiss JS; Harper JC; Del Rosso JQ; Bunick CG; Bhatia N; Tanghetti EA; Eichenfield LF; Baldwin H; Draelos ZD; Callender VD; Han G; Gooderham MJ; Sadick N; Lupo MP; Lain ET; Werschler WP
    Dermatol Ther (Heidelb); 2024 May; 14(5):1211-1227. PubMed ID: 38724841
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% for the once-daily treatment of moderate to severe acne vulgaris.
    Pariser DM; Rich P; Cook-Bolden FE; Korotzer A
    J Drugs Dermatol; 2014 Sep; 13(9):1083-9. PubMed ID: 25226009
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Triple-combination clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15% gel for moderate-to-severe acne in children and adolescents: Randomized phase 2 study.
    Eichenfield LF; Stein Gold L; Kircik LH; Werschler WP; Beer K; Draelos ZD; Tanghetti EA; Papp KA; Baldwin H; Lain E; Sadick N; Gooderham MJ; Konda A
    Pediatr Dermatol; 2023; 40(3):452-459. PubMed ID: 36949579
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized, double-blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris.
    Cunliffe WJ; Holland KT; Bojar R; Levy SF
    Clin Ther; 2002 Jul; 24(7):1117-33. PubMed ID: 12182256
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once-daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients.
    Thiboutot D; Zaenglein A; Weiss J; Webster G; Calvarese B; Chen D
    J Am Acad Dermatol; 2008 Nov; 59(5):792-800. PubMed ID: 18805603
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Profile of clindamycin phosphate 1.2%/benzoyl peroxide 3.75% aqueous gel for the treatment of acne vulgaris.
    Nguyen TA; Eichenfield LF
    Clin Cosmet Investig Dermatol; 2015; 8():549-54. PubMed ID: 26604811
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early and Sustained Acne Lesion Reductions With Fixed-Dose Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel.
    Harper JC; Kircik LH; Gold M; Hebert AA; Sugarman JL; Green L; Gold LS; Baldwin H; Guenin E; DelRosso JQ
    J Drugs Dermatol; 2024 Mar; 23(3):125-131. PubMed ID: 38443130
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double-blind investigations.
    Lookingbill DP; Chalker DK; Lindholm JS; Katz HI; Kempers SE; Huerter CJ; Swinehart JM; Schelling DJ; Klauda HC
    J Am Acad Dermatol; 1997 Oct; 37(4):590-5. PubMed ID: 9344199
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The efficacy and tolerability of a fixed combination clindamycin (1.2%) and benzoyl peroxide (3.75%) aqueous gel in patients with facial acne vulgaris: gender as a clinically relevant outcome variable.
    Harper JC
    J Drugs Dermatol; 2015 Apr; 14(4):381-4. PubMed ID: 25844612
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A combination benzoyl peroxide and clindamycin topical gel compared with benzoyl peroxide, clindamycin phosphate, and vehicle in the treatment of acne vulgaris.
    Tschen EH; Katz HI; Jones TM; Monroe EW; Kraus SJ; Connolly MA; Levy SF
    Cutis; 2001 Feb; 67(2):165-9. PubMed ID: 11236229
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fitzpatrick skin types and clindamycin phosphate 1.2%/benzoyl peroxide gel: efficacy and tolerability of treatment in moderate to severe acne.
    Callender VD
    J Drugs Dermatol; 2012 May; 11(5):643-8. PubMed ID: 22527435
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clindamycin phosphate 1·2%-benzoyl peroxide 3·0% fixed-dose combination gel has an effective and acceptable safety and tolerability profile for the treatment of acne vulgaris in Japanese patients: a phase III, multicentre, randomised, single-blinded, active-controlled, parallel-group study.
    Kawashima M; Hashimoto H; Alió Sáenz AB; Ono M; Yamada M
    Br J Dermatol; 2015 Feb; 172(2):494-503. PubMed ID: 25040180
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gender as a clinically relevant outcome variable in acne: benefits of a fixed combination clindamycin phosphate (1.2%) and benzoyl peroxide (2.5%) aqueous gel.
    Harper JC
    J Drugs Dermatol; 2012 Dec; 11(12):1440-5. PubMed ID: 23377514
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Moderate and Severe Inflammatory Acne Vulgaris Effectively Treated with Single-Agent Therapy by a New Fixed-Dose Combination Adapalene 0.3 %/Benzoyl Peroxide 2.5 % Gel: A Randomized, Double-Blind, Parallel-Group, Controlled Study.
    Stein Gold L; Weiss J; Rueda MJ; Liu H; Tanghetti E
    Am J Clin Dermatol; 2016 Jun; 17(3):293-303. PubMed ID: 26945741
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A multicentre, randomized, single-blind comparison of topical clindamycin 1%/benzoyl peroxide 5% once-daily gel versus clindamycin 1% twice-daily gel in the treatment of mild to moderate acne vulgaris in Chinese patients.
    Xu JH; Lu QJ; Huang JH; Hao F; Sun QN; Fang H; Gu J; Dong XQ; Zheng J; Luo D; Li FQ; Wang G; Gu H; Tian HQ; Yang HL; Xi LY; Li M; Zheng M; Wu Y; Tu YT; He YL; Zhao G; Sheng WX; Li J; Hamedani AG
    J Eur Acad Dermatol Venereol; 2016 Jul; 30(7):1176-82. PubMed ID: 27075705
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of Moderate-to-severe Acne Vulgaris in a Hispanic Population: A
    Alexis AF; Cook-Bolden F; Lin T
    J Clin Aesthet Dermatol; 2017 Jun; 10(6):36-43. PubMed ID: 28979655
    [No Abstract]   [Full Text] [Related]  

  • 37. A randomized, single-blind comparison of topical clindamycin + benzoyl peroxide and adapalene in the treatment of mild to moderate facial acne vulgaris.
    Langner A; Chu A; Goulden V; Ambroziak M
    Br J Dermatol; 2008 Jan; 158(1):122-9. PubMed ID: 18047518
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cutaneous Safety and Tolerability of a Fixed Combination Clindamycin (1.2%) and Benzoyl Peroxide (3.75%) Aqueous Gel in Moderate-to-severe Acne Vulgaris.
    Webster G
    J Clin Aesthet Dermatol; 2015 Aug; 8(8):22-8. PubMed ID: 26345297
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and Tolerability of a Novel Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate or Severe Acne Vulgaris in Adult Females.
    Harper JC; Baldwin H; Stein Gold L; Guenin E
    J Drugs Dermatol; 2019 Nov; 18(11):1147-1154. PubMed ID: 31741360
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clindamycin/benzoyl peroxide gel (BenzaClin): a review of its use in the management of acne.
    McKeage K; Keating GM
    Am J Clin Dermatol; 2008; 9(3):193-204. PubMed ID: 18429651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.